A recent meta-analysis indicated that high ERCC1 level was a positive prognostic factor, being associated with shorter survival and lower response to platinum-based chemotherapy in advanced NSCLC patients [23]. This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.